{"id":"W4226117846","doi":"10.1016/j.annonc.2022.02.029","title":"20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Janssen Biotech; Sanofi Genzyme; EMD Serono; Nordic Pharma Group; Ono Pharmaceutical; Eisai; Merck KGaA; Yuhan; Puma Biotechnology; Teva Pharmaceutical Industries; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Oncology; Internal medicine; Chemotherapy; non-small cell lung cancer (NSCLC); Population; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002477258,0.0002048777,0.0002726574,0.0003546884,0.0002784793,0.0004150403,0.0002320572,0.0004810853,0.0008088686],"category_scores_gemma":[0.001303761,0.00008574918,0.0003236592,0.0002241781,0.0001534671,0.0003782156,0.0002349102,0.000796558,0.000149346],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004498395,"about_ca_system_score_gemma":0.0004640803,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009104087,"about_ca_topic_score_gemma":0.002075479,"domain_scores_codex":[0.9998686,0.00002292996,0.00001338152,0.00001396527,0.00005095727,0.00003008191],"domain_scores_gemma":[0.9997136,0.00007019495,0.00007924624,0.000008357384,0.00002639671,0.0001021876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01238368,0.001024187,0.6251773,0.0002343976,0.0005316069,0.02900963,0.000228278,0.002186959,0.01162384,0.000937798,0.0082376,0.3084247],"study_design_scores_gemma":[0.0003568366,0.00575529,0.9162008,0.0002316709,0.0006487682,0.05341896,0.0003125205,0.004932742,0.004041816,0.002443407,0.01159852,0.00005879026],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828304,0.006457688,0.0003932895,0.001687826,0.00008803498,0.00003011933,0.0001327766,0.00002829644,0.008351572],"genre_scores_gemma":[0.9970146,0.001495653,0.0002404426,0.000381166,0.0001254189,0.00001544438,0.0001800746,0.000007092253,0.0005400555],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009104087,"threshold_uncertainty_score":0.003263831,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02815589383460161,"score_gpt":0.3790767388232577,"score_spread":0.3509208449886561,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}